sur IKONISYS (EPA:ALIKO)
Ikonisys SA Reports Increased Revenues and Developments in 2025
Ikonisys SA, now trading as Aliko Scientific, announced a 52.6% revenue increase to €1.64 million for 2025, aided by Hospitex's full-year contribution and the rollout of Aliko Scientific’s offerings. The company reduced its EBITDA loss by 32.9% to €1.14 million.
Key developments include the US patent for ACTA, the launch of Urine24, and a distribution deal with Menarini Diagnostics. CEO Francesco Trisolini highlighted the transformation under the Aliko brand as a significant step towards building an integrated oncology diagnostics platform.
The 2025 financial statements reflected growth, but also a net loss increase to €4.20 million due to accelerated amortization charges. Cash reserves rose significantly to €1.03 million by year-end.
Aliko's strategy emphasizes expanding international distribution, integrating products, and boosting recurring revenues from consumables and services. The 2025 Annual Financial Report is available from July 31, 2026.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de IKONISYS